ENDP stock: buy or sell?
September 20th, 2019
Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets.
Should I buy ENDP stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Endo International stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Endo International stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 13 ratings published for ENDP stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-8||Royal Bank of Canada||n/a||Hold|
|2019-7-15||Morgan Stanley||Equal Weight||Underweight|
|2019-7-11||Royal Bank of Canada||Outperform||Sector Perform|
|2019-5-13||JPMorgan Chase & Co.||Neutral||Underweight|
|2019-3-5||Svb Leerink||Outperform||Market Perform|
|2019-3-5||Leerink Swann||Outperform||Market Perform|
|2019-3-18||JPMorgan Chase & Co.||Neutral||Neutral|
ENDP stock analysis
After sliding a spooky -14.88% yesterday, Endo International closed today at $3.48 and skyrocketed a great 3.57%.
After sliding a spooky -14.88% yesterday, Endo International closed today at $3.48 and skyrocketed a great 3.57%. ENDP is retaking the upward trend marking a new rising bottom heading to break out over $4.46. On Sep/10 ENDP price bounced up over the SMA of 50 days demonstrating to be a significant support for this stock.
After boosting an amazing 10.05% in a week last week, Endo International closed this week at $3.48 and collapsed a spooky -10.31%.
Since price and 40-weeks moving average lines crossed down by mid December 2018, ENDP fell $-8.09 per share (-69.92%). Stocks below the 40-weeks moving average line are usually not recommended for average traders.
ENDP stock price history
ENDP IPO was on July 18th, 2000 at $14.50 per share1. Since then, ENDP stock lost a -76.00%, with a yearly average of -4.00%.
1: Adjusted price after possible price splits or reverse-splits.
ENDP stock historical price chart
ENDP stock reached 52-week highs on October at $18.50, and all-time highs 2015-04-16 with a price of 96.58.
ENDP stock price target is $6.20How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ENDP stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 10 price targets for ENDP stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-8||Royal Bank of Canada||Reiterates||n/a||$6.00||-|
|2019-7-11||Royal Bank of Canada||Downgrades||$11.00||$6.00||-45.5%|
|2019-5-13||JPMorgan Chase & Co.||Downgrades||n/a||$9.00||-|
|2019-3-18||JPMorgan Chase & Co.||Lowers Target||$16.00||$10.00||-37.5%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Endo International reported its latest financial data, posting an astounding climb for the Earnings per Share (EPS) ratio. Analyst expected $0.59 per share, but Endo International posted $0.75.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Endo International annual turnover plunged a frightening -15.04% to $2,947.08 M dollars from $3,468.86 marked in 2017. When comparing 2018 vs 2017, in contrary, profit margin (that is, the net income divided by revenues) boosted a 23.68% to -35.00%.
|2013||$2,620 M||-||$-535.50 M-20.4%||-|
|2014||$2,877 M||9.82%||$-721.32 M-25.1%||34.70%|
|2015||$3,269 M||13.61%||$-1,495.04 M-45.7%||107.26%|
|2016||$4,010 M||22.69%||$-3,347.07 M-83.5%||123.88%|
|2017||$3,469 M||-13.50%||$-2,035.43 M-58.7%||-39.19%|
|2018||$2,947 M||-15.04%||$-1,031.47 M-35.0%||-49.32%|
Quarterly financial resultsEndo International reported $786.39 M in revenues for 2018-Q4, a 5.49% improvement compared to previous quarter. Reported quarter income marked $-291.91 million with a profit margin of -37.12%. Profit margin collapsed a -13.89% compared to previous quarter when profit margin was -23.23%. When comparing revenues to same quarter last year, Endo International sales marked a tiny growth and raised a 2.31%. Looking back to recent quarterly results, Endo International posted 3 negative quarters in a row.
|2017-Q1||$1,040 M||-||$-165.42 M-15.9%||-|
|2017-Q2||$876 M||-15.80%||$-696.02 M-79.5%||320.76%|
|2017-Q3||$787 M||-10.15%||$-96.67 M-12.3%||-86.11%|
|2017-Q4||$769 M||-2.32%||$-368.42 M-47.9%||281.11%|
|2018-Q1||$701 M||-8.86%||$-505.49 M-72.2%||37.21%|
|2018-Q2||$715 M||2.02%||$-60.87 M-8.5%||-87.96%|
|2018-Q3||$745 M||4.31%||$-173.21 M-23.2%||184.56%|
|2018-Q4||$786 M||5.49%||$-291.91 M-37.1%||68.53%|
Endo International ownershipWhen you are planning to buy shares of a company, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Endo International, 0.21% of all outstanding shares are owned by its staff.
Bearish positions for ENDP stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$787.8 M||$419.8 M||$1.1 B||$364.7 M||$205.0 M|
|Total shares||226.4 M||89.5 M||46.6 M||191.9 M||84.0 M|
|Float shares||176.5 M||68.9 M||42.1 M||166.6 M||83.1 M|
|- Institutional holdings (%)||96.7%||58.8%||62.4%||46.1%||113.9%|
|- Insider holdings (%)||0.2%||6.0%||2.9%||4.0%||2.2%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$3.33 - $3.67|
|Average true range||$0.53|
|50d mov avg||$3.05|
|100d mov avg||$4.23|
|200d mov avg||$6.65|
Endo International performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Endo International against BioDelivery Sciences International, Cara Therapeutics, DURECT, Mallinckrodt and Zogenix in the following table: